155 related articles for article (PubMed ID: 30659272)
1. High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer.
Nguyen HT; Migliozzi D; Bisig B; de Leval L; Gijs MAM
Lab Invest; 2019 May; 99(5):722-732. PubMed ID: 30659272
[TBL] [Abstract][Full Text] [Related]
2. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
[TBL] [Abstract][Full Text] [Related]
3. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.
Onsum MD; Geretti E; Paragas V; Kudla AJ; Moulis SP; Luus L; Wickham TJ; McDonagh CF; MacBeath G; Hendriks BS
Am J Pathol; 2013 Nov; 183(5):1446-1460. PubMed ID: 24035511
[TBL] [Abstract][Full Text] [Related]
4. [Intratumoral heterogeneity of HER2 status in breast carcinoma].
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
Pathologe; 2010 Oct; 31 Suppl 2():292-5. PubMed ID: 20652266
[TBL] [Abstract][Full Text] [Related]
5. Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer.
Dupouy DG; Ciftlik AT; Fiche M; Heintze D; Bisig B; de Leval L; Gijs MA
Sci Rep; 2016 Feb; 6():20277. PubMed ID: 26856369
[TBL] [Abstract][Full Text] [Related]
6. Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens.
Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
Diagn Pathol; 2013 Feb; 8():17. PubMed ID: 23379971
[TBL] [Abstract][Full Text] [Related]
7. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
9. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
Kondo Y; Kikuchi T; Esteban JC; Kumaki N; Ogura G; Inomoto C; Hirabayashi K; Kajiwara H; Sakai A; Sugimoto R; Otsuru M; Okami K; Tsukinoki K; Nakamura N
Pathol Int; 2014 Sep; 64(9):453-9. PubMed ID: 25209856
[TBL] [Abstract][Full Text] [Related]
11. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
13. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
14. Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.
Nie X; He J; Li Y; Pan DZ; Pan HX; Weng MX; Yang XP; Liu CP; Huang T
J Huazhong Univ Sci Technolog Med Sci; 2013 Jun; 33(3):379-384. PubMed ID: 23771664
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.
Yang YL; Fan Y; Lang RG; Gu F; Ren MJ; Zhang XM; Yin D; Fu L
Breast Cancer Res Treat; 2012 Aug; 134(3):1095-102. PubMed ID: 22476857
[TBL] [Abstract][Full Text] [Related]
16. HER2 Immunohistochemistry-Guided Targeted Fluorescence In Situ Hybridization Analysis Does Not Help Identify Intratumoral Heterogeneity in Breast Cancer.
Gulbahce HE; Factor R; Geiersbach K; Downs-Kelly E
Arch Pathol Lab Med; 2016 Aug; 140(8):741. PubMed ID: 27472230
[No Abstract] [Full Text] [Related]
17. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
[TBL] [Abstract][Full Text] [Related]
18. Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
Viale G; Paterson J; Bloch M; Csathy G; Allen D; Dell'Orto P; Kjærsgaard G; Levy YY; Jørgensen JT
Pathol Res Pract; 2016 Aug; 212(8):735-42. PubMed ID: 27461826
[TBL] [Abstract][Full Text] [Related]
19. A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
Nishida Y; Kuwata T; Nitta H; Dennis E; Aizawa M; Kinoshita T; Ohtsu A; Ochiai A
Gastric Cancer; 2015 Jul; 18(3):458-66. PubMed ID: 24917219
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Partial Weak Staining in Normal Breast Epithelium on the Reliability of Immunohistochemistry Results in HercepTest-positive Breast Cancer.
Farra C; Fedda F; Tfayli A; Tawil A; Zaatari G; Ashkar H; Issa G; Boulos F
Clin Breast Cancer; 2019 Oct; 19(5):340-344. PubMed ID: 31213407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]